[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632906":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":34,"centralContacts":38,"locations":45,"responsibleParty":218,"collaborators":43,"id":220,"slug":221,"hasResults":222,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":43,"eligibilityCriteria":226,"healthyVolunteers":222,"sex":227,"minAge":228,"maxAge":43,"enrollmentInfo":229,"targetDuration":43,"studyType":232,"phases":233,"briefSummary":236,"conditions":237,"keywords":43,"overallStatus":48,"whyStopped":43,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":250},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Follicular Lymphoma (FL) MK-1045 Monotherapy Dose Optimization","EXPERIMENTAL","Participants will receive Dosage A of MK-1045 by Intravenous (IV) infusion for up to approximately 1 year of treatment or until discontinuation.",[13],"Biological: MK-1045",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2: FL MK-1045 Longer Dosing Interval","Participants will receive Dosage B of MK-1045 by Intravenous (IV) infusion for up to approximately 1 year of treatment or until discontinuation.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Arm 3: FL MK-1045 Subcutaneous Administration","Participants will receive Dosage C of MK-1045 by subcutaneous (SC) injection for up to approximately 1 year of treatment or until discontinuation.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Arm 4: Diffuse Large B-cell Lymphoma (DLBCL) MK-1045 Monotherapy Dose Optimization","Participants will receive Dosage D of MK-1045 by Intravenous (IV) infusion for up to approximately 1 year of treatment or until discontinuation.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","MK-1045","Intravenous (IV) Infusion or Subcutaneous (SC) injection",[9,15,19,23],[33],"CN-201",[35],{"name":36,"affiliation":5,"role":37},"Medical Director","STUDY_DIRECTOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Toll Free Number","CONTACT","1-888-577-8839",null,"Trialsites@msd.com",[46,64,79,93,102,114,126,141,156,169,183,195,204],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Sanatorio Nuestra Senora del Rosario ( Site 1403)","RECRUITING","Rosario","Santa Fe Province","2001","Argentina","AR",{"type":55,"coordinates":56},"Point",[57,58],-60.63932,-32.94682,{"lat":58,"lon":57},[61],{"name":62,"role":41,"phone":63,"phoneExt":43,"email":43},"Study Coordinator","+5493416149225",{"facility":65,"status":48,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Beijing Cancer hospital ( Site 1701)","Beijing","Beijing Municipality","100142","China","CN",{"type":55,"coordinates":72},[73,74],116.39723,39.9075,{"lat":74,"lon":73},[77],{"name":62,"role":41,"phone":78,"phoneExt":43,"email":43},"+86 010-88196922",{"facility":80,"status":48,"city":81,"state":43,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Shaare Zedek Medical Center ( Site 0603)","Jerusalem","9103102","Israel","IL",{"type":55,"coordinates":86},[87,88],35.21633,31.76904,{"lat":88,"lon":87},[91],{"name":62,"role":41,"phone":92,"phoneExt":43,"email":43},"+972544922952",{"facility":94,"status":48,"city":81,"state":43,"zip":95,"country":83,"countryCode":84,"cosmosGeoPoint":96,"geoPoint":98,"contacts":99},"Haddasah Medical Center ( Site 0600)","9112001",{"type":55,"coordinates":97},[87,88],{"lat":88,"lon":87},[100],{"name":62,"role":41,"phone":101,"phoneExt":43,"email":43},"+972539101736",{"facility":103,"status":48,"city":104,"state":43,"zip":105,"country":83,"countryCode":84,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Sheba Medical Center ( Site 0601)","Ramat Gan","5265601",{"type":55,"coordinates":107},[108,109],34.81065,32.08227,{"lat":109,"lon":108},[112],{"name":62,"role":41,"phone":113,"phoneExt":43,"email":43},"97235303030",{"facility":115,"status":48,"city":116,"state":43,"zip":117,"country":83,"countryCode":84,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Sourasky Medical Center. ( Site 0604)","Tel Aviv","6423906",{"type":55,"coordinates":119},[120,121],34.78057,32.08088,{"lat":121,"lon":120},[124],{"name":62,"role":41,"phone":125,"phoneExt":43,"email":43},"+97236974444",{"facility":127,"status":48,"city":128,"state":129,"zip":130,"country":131,"countryCode":132,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Istituto di Candiolo - IRCCS ( Site 0701)","Candiolo","Piedmont","10060","Italy","IT",{"type":55,"coordinates":134},[135,136],7.59812,44.95858,{"lat":136,"lon":135},[139],{"name":62,"role":41,"phone":140,"phoneExt":43,"email":43},"+390119933355",{"facility":142,"status":48,"city":143,"state":144,"zip":145,"country":146,"countryCode":147,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 0900)","Warsaw","Masovian Voivodeship","02-781","Poland","PL",{"type":55,"coordinates":149},[150,151],21.01178,52.22977,{"lat":151,"lon":150},[154],{"name":62,"role":41,"phone":155,"phoneExt":43,"email":43},"+48225462000",{"facility":157,"status":48,"city":158,"state":159,"zip":160,"country":146,"countryCode":147,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Pratia Onkologia Katowice ( Site 0902)","Katowice","Silesian Voivodeship","40-519",{"type":55,"coordinates":162},[163,164],19.02173,50.2597,{"lat":164,"lon":163},[167],{"name":62,"role":41,"phone":168,"phoneExt":43,"email":43},"+48501714019",{"facility":170,"status":48,"city":171,"state":43,"zip":172,"country":173,"countryCode":174,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Hospital Universitari Vall de Hebron ( Site 1102)","Barcelona","08035","Spain","ES",{"type":55,"coordinates":176},[177,178],2.15899,41.38879,{"lat":178,"lon":177},[181],{"name":62,"role":41,"phone":182,"phoneExt":43,"email":43},"+34 932746000",{"facility":184,"status":48,"city":185,"state":43,"zip":186,"country":173,"countryCode":174,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Hospital Universitario Gregorio Maranon ( Site 1101)","Madrid","28007",{"type":55,"coordinates":188},[189,190],-3.70256,40.4165,{"lat":190,"lon":189},[193],{"name":62,"role":41,"phone":194,"phoneExt":43,"email":43},"+34915868888",{"facility":196,"status":48,"city":185,"state":43,"zip":197,"country":173,"countryCode":174,"cosmosGeoPoint":198,"geoPoint":200,"contacts":201},"Hospital Universitario 12 de Octubre ( Site 1105)","28041",{"type":55,"coordinates":199},[189,190],{"lat":190,"lon":189},[202],{"name":62,"role":41,"phone":203,"phoneExt":43,"email":43},"+34917792809",{"facility":205,"status":48,"city":206,"state":43,"zip":207,"country":208,"countryCode":209,"cosmosGeoPoint":210,"geoPoint":214,"contacts":215},"The Christie NHS Foundation Trust ( Site 1300)","Manchester","M20 4BX","United Kingdom","UK",{"type":55,"coordinates":211},[212,213],-2.23743,53.48095,{"lat":213,"lon":212},[216],{"name":62,"role":41,"phone":217,"phoneExt":43,"email":43},"+4401614468201",{"type":219,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100632906","phase-1-a-clinical-study-of-mk-1045-in-people-with-non-hodgkin-lymphoma-mk-1045-008-100632906",false,"NCT07519772","A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","A Phase 1b\u002F2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.\n* Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).\n* DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.\n* Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).\n* Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.\n* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.\n* Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.\n* Has undetectable hepatitis C virus (HCV) viral load and received HCV antiviral therapy if has a history of HCV infection.\n* Has radiographically measurable disease per Lugano Response Criteria.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has received a solid organ transplant.\n* Had or has clinically relevant central nervous system (CNS) diseases.\n* Has a history of serious cardiovascular or cerebrovascular diseases.\n* Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.\n* Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has received a live or live-attenuated vaccine within 30 days of randomization.\n* Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.\n* Has a known additional malignancy that is progressing or required active treatment within the past 2 years.\n* Has known active CNS lymphoma or involvement.\n* Has active autoimmune disease that required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has a history of severe bleeding disorders.\n* Has not recovered from major surgery or has ongoing surgical complications.\n* Has diagnosis of primary mediastinal B-cell lymphoma.","ALL","18 Years",{"count":230,"type":231},200,"ESTIMATED","INTERVENTIONAL",[234,235],"PHASE1","PHASE2","Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system.\n\nIn this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer.\n\nThe goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.",[238,239,240],"Lymphoma, Non-Hodgkin","Lymphoma, Follicular","Lymphoma, Large B-Cell, Diffuse","2026-07-01",{"date":243,"type":244},"2026-07-02","ACTUAL",{"date":246,"type":244},"2026-05-03",{"date":248,"type":231},"2031-04-01",{"name":5,"class":6},13]